BioLife Sciences Inc
BioLife Sciences Inc. develops, licenses, and commercializes products and technologies for the healthcare, beauty, and food and beverage industries. It also offers orthomolecular products. The company is based in Henderson, Nevada.
BioLife Sciences Inc (BLFE) - Total Assets
Latest total assets as of February 2022: $1.04K USD
Based on the latest financial reports, BioLife Sciences Inc (BLFE) holds total assets worth $1.04K USD as of February 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioLife Sciences Inc - Total Assets Trend (2004–2020)
This chart illustrates how BioLife Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioLife Sciences Inc - Asset Composition Analysis
Current Asset Composition (November 2020)
BioLife Sciences Inc's total assets of $1.04K consist of 98.6% current assets and 1.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $195.28K | 268.5% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2020)
This chart illustrates how BioLife Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioLife Sciences Inc's current assets represent 98.6% of total assets in 2020, a decrease from 100.0% in 2004.
- Cash Position: Cash and equivalents constituted 47.8% of total assets in 2020, up from 0.0% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is property, plant & equipment at 268.5% of total assets.
BioLife Sciences Inc Competitors by Total Assets
Key competitors of BioLife Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
OJsys Inc
PINK:OJSY
|
USA | $8.03 Million |
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
BioLife Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - BioLife Sciences Inc generates 5.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioLife Sciences Inc is currently not profitable relative to its asset base.
BioLife Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.15 | 2.35 |
| Quick Ratio | 0.07 | 0.15 | 2.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.06K | $ -798.07K | $ 45.74K |
BioLife Sciences Inc - Advanced Valuation Insights
This section examines the relationship between BioLife Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 427652.9% |
| Total Assets | $72.72K |
| Market Capitalization | $0.91 USD |
Valuation Analysis
Below Book Valuation: The market values BioLife Sciences Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BioLife Sciences Inc's assets grew by 427652.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BioLife Sciences Inc (2004–2020)
The table below shows the annual total assets of BioLife Sciences Inc from 2004 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-11-30 | $72.72K | +427652.94% |
| 2019-11-30 | $17.00 | -98.71% |
| 2018-11-30 | $1.32K | -89.30% |
| 2017-11-30 | $12.34K | -99.67% |
| 2007-11-30 | $3.76 Million | +8.29% |
| 2006-11-30 | $3.47 Million | +110.28% |
| 2005-11-30 | $1.65 Million | +1810.95% |
| 2004-11-30 | $86.45K | -- |